We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
Read MoreHide Full Article
Protagonist Therapeutics, Inc. (PTGX - Free Report) announced that the FDA has granted an orphan drug designation to its injectable hepcidin mimetic PTG-300 for the treatment of polycythemia vera. The candidate is an injectable synthetic peptide mimetic of the natural hormone hepcidin, which is also being developed for treating hereditary hemochromatosis.
Notably, orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits including tax credits related to clinical trial expenses and an exemption from the FDA user fee.
As per the press release, recently, the company announced initial data from a phase II study, which evaluated PTG-300 for the above-mentioned indication. In the study, PTG-300 demonstrated robust clinical response and clinically meaningful dose-related control of hematocrit levels on individual patient.
Shares of Protagonist Therapeutics have skyrocketed 129.6% so far this year compared with the industry’s rally of 8.2%.
Meanwhile, the company discontinued the clinical development of PTG-300 for beta-thalassemia and myelodysplastic syndromes. The company redirected majority of its efforts to develop PTG-300 for the polycythemia vera and hereditary hemochromatosis indication.
Apart from PTG-300, Protagonist Therapeutics is developing two other candidates, namely PTG-200 and PN-943 for addressing inflammatory bowel diseases.
Notably, in the fourth quarter of 2019, Protagonist Therapeutics in collaboration with Janssen Biotech, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) , initiated a phase II study on PTG-200, an oral IL-23 receptor antagonist, for the treatment of moderate-to-severe Crohn's disease.
Protagonist Therapeutics is also developing PN-943, an oral alpha-4-beta-7 integrin antagonist, for the treatment of inflammatory bowel disease. The company plans to begin a phase II study on the same for treating ulcerative colitis.
Zacks Rank & Stocks to Consider
Protagonist Therapeutics currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Ligand Pharmaceuticals Incorporated (LGND - Free Report) and NuCana PLC (NCNA - Free Report) , bothf currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings estimates have been revised 7.2% upward for 2020 and 10% for 2021 over the past 60 days. The stock has gained 6.7% year to date.
NuCana’s loss per share estimates have narrowed 17% for 2020 and 18.1% for 2021 over the past 60 days.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Image: Bigstock
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
Protagonist Therapeutics, Inc. (PTGX - Free Report) announced that the FDA has granted an orphan drug designation to its injectable hepcidin mimetic PTG-300 for the treatment of polycythemia vera. The candidate is an injectable synthetic peptide mimetic of the natural hormone hepcidin, which is also being developed for treating hereditary hemochromatosis.
Notably, orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits including tax credits related to clinical trial expenses and an exemption from the FDA user fee.
As per the press release, recently, the company announced initial data from a phase II study, which evaluated PTG-300 for the above-mentioned indication. In the study, PTG-300 demonstrated robust clinical response and clinically meaningful dose-related control of hematocrit levels on individual patient.
Shares of Protagonist Therapeutics have skyrocketed 129.6% so far this year compared with the industry’s rally of 8.2%.
Meanwhile, the company discontinued the clinical development of PTG-300 for beta-thalassemia and myelodysplastic syndromes. The company redirected majority of its efforts to develop PTG-300 for the polycythemia vera and hereditary hemochromatosis indication.
Apart from PTG-300, Protagonist Therapeutics is developing two other candidates, namely PTG-200 and PN-943 for addressing inflammatory bowel diseases.
Notably, in the fourth quarter of 2019, Protagonist Therapeutics in collaboration with Janssen Biotech, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) , initiated a phase II study on PTG-200, an oral IL-23 receptor antagonist, for the treatment of moderate-to-severe Crohn's disease.
Protagonist Therapeutics is also developing PN-943, an oral alpha-4-beta-7 integrin antagonist, for the treatment of inflammatory bowel disease. The company plans to begin a phase II study on the same for treating ulcerative colitis.
Zacks Rank & Stocks to Consider
Protagonist Therapeutics currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Ligand Pharmaceuticals Incorporated (LGND - Free Report) and NuCana PLC (NCNA - Free Report) , bothf currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings estimates have been revised 7.2% upward for 2020 and 10% for 2021 over the past 60 days. The stock has gained 6.7% year to date.
NuCana’s loss per share estimates have narrowed 17% for 2020 and 18.1% for 2021 over the past 60 days.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>